Hellenic journal of nuclear medicine最新文献

{"title":"Salivary scintigraphy as a pre-treatment diagnostic tool to predict gland dysfunction following ¹³¹I therapy.","authors":"Hui Zhu, Wei Shen, Yuan Zhu, Zhao Liu, Zhiyong Li, Xiancun Hou, Yuetao Wang","doi":"10.1967/s002449912801","DOIUrl":"10.1967/s002449912801","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate whether pre-treatment salivary gland scintigraphy (SGS) with technetium-99m pertechnetate (^99mTcO₄^-) can predict the risk of moderate to severe salivary gland dysfunction and xerostomia in differentiated thyroid cancer (DTC) patients following their first radioiodine-131 (¹³¹I) therapy.</p><p><strong>Subjects and methods: </strong>We retrospectively enrolled 149 DTC patients (107 females, 42 males; mean age 46.6±12.7 years) who underwent total thyroidectomy between October 2022 and March 2024. All subjects received pre-treatment SGS to measure the uptake index (UI) and excretion fraction (EF) of bilateral parotid and submandibular glands. Patients then underwent ¹³¹I therapy (1.85-5.55GBq) and repeat SGS 6-12 months later under identical conditions. Xerostomia severity was assessed using the xerostomia inventory (XI) score, categorizing patients into no/mild (XI 11-23) versus moderate-extreme xerostomia (XI 24-55).</p><p><strong>Results: </strong>Post-therapy, all glands exhibited significant declines in UI (parotid and submandibular glands, P<0.001) and EF (P≤0.004). There was no significant correlation between administered ¹³¹I dose and percentage changes in UI (ΔUI%) or EF (ΔEF). However, higher ¹³¹I doses were associated with increased rates of moderate-severe xerostomia (P=0.015) and higher mean XI scores (P=0.008). Receiver operating characteristic (ROC) analysis demonstrated that pre-treatment UI reliably predicted moderate to severe functional decline (ΔUI% >20%) with areas under the curve (AUC) of 0.866 for the right parotid, 0.793 for the left parotid, 0.769 for the right submandibular, and 0.816 for the left submandibular glands (all P<0.001). Additionally, ΔUI% in both submandibular glands differed significantly between patients with no/mild and moderate-extreme xerostomia (right: P=0.004; left: P=0.012).</p><p><strong>Conclusion: </strong>Pretreatment ^99mTcO₄^- SGS uptake index is a dependable predictor of moderate to severe salivary gland dysfunction and xerostomia following ¹³¹I therapy in DTC patients, enabling early identification of individuals at high risk and guiding tailored preventive strategies.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"96-114"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness and reliability of ¹⁸I-6-β-iodomethyl- norcholesterol (NP-59), adrenal cortex scintigraphy in discrimination between adenoma and hyperplasia in case of a patient with primary hyperaldosteronism (PH) without discontinuation of antihypertension therapy.","authors":"Evangelos Karathanos, Irini Giagourta, Agaristi Kaspiri","doi":"10.1967/s002449912809","DOIUrl":"10.1967/s002449912809","url":null,"abstract":"<p><p>Clear iodine-131 (¹⁸I)-6-β-iodomethyl- norcholesterol aldosterinoma finding, proven on biopsy, without prior discontinuation of spironolactone (due to high blood pressure) reveals no changes on scintigraphic sensitivity.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"176-180"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"⁶⁸Ga-pentixafor for PET imaging of chemokine receptor 4 expression in lymphoproliferative diseases and solid tumors.","authors":"Tingwei Meng, Qingqing Pan, Yaping Luo","doi":"10.1967/s002449912803","DOIUrl":"10.1967/s002449912803","url":null,"abstract":"<p><strong>Objective: </strong>Gallium-68 (⁶⁸Ga)-pentixafor, a novel positron emission tomography (PET) tracer with high affinity for C-X-C motif chemokine receptor 4 (CXCR4), has recently been introduced in order to assess the CXCR4 expression status in vivo. This study is to investigate the role of ⁶⁸Ga-pentixafor in detecting various tumors with mice models and to provide references to clinical studies.</p><p><strong>Materials and methods: </strong>Gallium-68-pentixafor and fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) PET was performed in opm-2 (lymphoma), daudi (myeloma) and panc1 (pancreatic cancer)-bearing mice. Tumor and background tissue uptake between ⁶⁸Ga-pentixafor and ¹⁸F-FDG PET were compared. Gallium-68-pentixafor PET/computed tomography (CT) was performed in four patients with lymphoma and three patients with multiple myeloma, and ¹⁸F-FDG PET/CT was performed as a reference.</p><p><strong>Results: </strong>The uptake of ⁶⁸Ga-pentixafor in background tissues including muscle, liver and kidneys were all lower than those of ¹⁸F-FDG. The uptake of ⁶⁸Ga-pentixafor in the tumors of lymphoma and myeloma-bearing xenografts was comparable or higher than those of ¹⁸F-FDG. However, the tumors of panc-1 xenografts had much lower uptake of ⁶⁸Ga-pentixafor than those in lymphoma and myeloma-bearing mice, and it was also significantly lower than those of ¹⁸F-FDG. The high uptake of ⁶⁸Ga-pentixafor in vivo was confirmed by the high expression of CXCR4 in tumors with immunochemical analysis. Gallium-68-pentixafor PET/CT in patients with marginal zone lymphoma (MZL) and myeloma showed more intense uptake and more extensive involvement than ¹⁸F-FDG PET/CT did. Gallium-68-pentixafor and ¹⁸F-FDG PET/CT showed comparable uptake in the patient with follicular lymphoma.</p><p><strong>Conclusion: </strong>Gallium-68-pentixafor is a promising agent for the evaluation of lymphoproliferative diseases.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"124-130"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-FDG parameters as therapy response predictors in patients with diffuse large B-cell lymphoma: A single centre experience.","authors":"Milica Kotur, Nikola Pantić, Isidora Grozdić Milojević, Amin Mehmedović, Nikola Andrejić, Milica Stojiljković, Jelena Petrović, Dragana Šobić Šaranović, Vera Artiko, Strahinja Odalović","doi":"10.1967/s002449912802","DOIUrl":"10.1967/s002449912802","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study is to determine the importance of different fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography with computed tomography (PET/CT) semi-quantitative and quantitative parameters, as well as various clinical and demographic parameters, in predicting disease outcomes and response to therapy in patients with diffuse large B-cell lymphoma (DLBCL).</p><p><strong>Subjects and methods: </strong>The study included 64 patients diagnosed with DLBCL who underwent ¹⁸F-FDG PET/CT imaging between January 2020 and April 2023. Each patient underwent both an initial ¹⁸F-FDG PET/CT and an interim ¹⁸F-FDG PET/CT after 2 or 4 cycles of chemotherapy. The Deauville score (DS) was calculated for each patient. Progression-free survival (PFS) was defined as the time from the date of diagnosis to the first appearance of metabolic or morphological progression of pre-existing lesions and/or the appearance of new lesions detected on interim ¹⁸F-FDG PET/CT or follow-up radiological imaging, as well as in cases of death due to the underlying disease or until the end of the clinical follow-up period.</p><p><strong>Results: </strong>Among the clinical-demographic parameters analyzed, the only significant predictive factor was the international prognostic index (IPI) score, categorized by group. Of the ¹⁸F-FDG PET/CT parameters examined, DS showed strong statistical significance in both univariate and multivariate analyses. While maximum standardized uptake value (SUVmax) and peak SUV (SUVpeak) were statistically significant in the univariate analysis. Progression-free survival was longer in patients with an IPI ≤2 and DS ≤3, compared to those with higher IPI and DS.</p><p><strong>Conclusion: </strong>The results of this study showed that the early metabolic response to therapy assessed on the basis of interim ¹⁸F-FDG PET/CT is a significant independent predictive factor for disease outcome in patients with DLBCL.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"115-123"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative insights into mild cognitive impairment: A clinical case study with ¹⁸F-FDG and amyloid PET imaging.","authors":"Shiv Patil, Eric M Teichner, Robert C Subtirelu, Arjun B Ashok, Talha Khan, Alexander Gerlach, Raj Patel, Lancelot Herpin, Moein Moradpour, Thomas Werner, Andrew Newberg, Mona Elisabeth Revheim, Abass Alavi","doi":"10.1967/s002449912807","DOIUrl":"10.1967/s002449912807","url":null,"abstract":"<p><p>Early detection of mild cognitive impairment (MCI) is crucial for initiating therapeutic interventions that may slow or prevent further cognitive deterioration. Mild cognitive impairment represents a transitional phase between normal cognitive aging and more severe forms of dementia, such as Alzheimer's disease (AD). Positron emission tomography (PET) can provide insight into the pathophysiology and progression of neurodegenerative processes associated with dementia and MCI using either fluorine-18 (¹⁸F)-florbetapir, which detects beta-amyloid plaque burden, or ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG), which measures glucose metabolism. However, there are limited comparative studies using the two radiotracers to quantify cognitive decline. This case study presents an 83-year-old female with a clinical diagnosis of MCI and a mini-mental state examination (MMSE) score of 26, at the lower boundary for normal cognitive function; she was assessed with PET/computed tomography (CT) using both radiotracers. Although global assessments did not reveal significant abnormalities, localized findings showed hypometabolism in key brain regions, such as the posterior cingulate cortex, and beta-amyloid plaque accumulation in the anterior cingulate cortex. These results highlight the limitations of conventional cognitive assessments, like the MMSE, and underscore the potential value of PET imaging as a complementary diagnostic tool. The study supports the role of ¹⁸F-FDG as a stronger indicator of cognitive impairment due to its correlation with cognitive scores, while recognizing the need for further research to evaluate the predictive value of both PET tracers in early MCI detection and their potential to improve diagnostic accuracy.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"168-172"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of splenic scintigraphy in the diagnosis of thoracic nodules.","authors":"Hamdi Afşin, Emine Afsin, Billur Çalışkan","doi":"10.1967/s002449912808","DOIUrl":"10.1967/s002449912808","url":null,"abstract":"<p><p>Thoracic splenosis is the presence of acquired ectopic splenic tissue within the thoracic cavity, typically following thoracoabdominal trauma or surgery. It is mostly asymptomatic and detected incidentally on radiography or tomography. A 64-year-old man was admitted with exertional dyspnea without any other respiratory complaints. The patient had a history of diabetes mellitus and hypertension and had undergone bilateral lung surgery and splenectomy due to a traffic accident 30 years ago. Thoracic computed tomograph (CT) revealed an 11x7mm nodular lesion in the posterobasal lower lobe of the left lung, multiple millimetric nodular lesions in the pleura corresponding to the left lung operation site, a focal defect in the right diaphragm, and liver herniation in this area. The diagnosis of \"thoracic splenosis\" was made by splenic scintigraphy.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"173-175"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"⁶⁸Ga-FAPI PET/CT for diagnosing multifocal head-neck and liver paragangliomas.","authors":"Jing Zhou, Longlan Chen, Ruyan Liu, Yigang Zhao","doi":"10.1967/s002449912810","DOIUrl":"10.1967/s002449912810","url":null,"abstract":"<p><p>This report presents a case of a 51-year-old woman who was admitted to our hospital with incomplete closure of the left eyelid and a crooked right corner of the mouth. She was diagnosed with multifocal head-neck and liver paragangliomas that were confirmed by pathological tests and gallium-68-fibroblast activation protein inhibitor (⁶⁸Ga-FAPI) positron emission tomography/computed tomography (PET/CT) imaging. The findings of this case suggest that ⁶⁸Ga-FAPI PET/CT may be a potential diagnostic tool for paragangliomas.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"181-182"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head-to-head comparison of ¹⁸F-FDG versus ¹⁸F-FAPI-74 PET in radioactive-iodine refractory differentiated thyroid cancer patients.","authors":"Panayiotis Hadjitheodorou, Wolfgang Roll, Emmanouil Alevroudis, Kyriaki Kyrou, Giorgos Adamou, Andreas Fesas, Mohammad Reza Pourkhessalian, Charalambia Kalogirou, Ioannis Tsechelidis, Alexis Vrachimis","doi":"10.1967/s002449912780","DOIUrl":"10.1967/s002449912780","url":null,"abstract":"<p><strong>Objective: </strong>Fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) was reported to outperform fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) PET/CT in thyroid cancer in heterogenous patient collectives. This interim analysis of a prospective study aims to determine whether ¹⁸F-FAPI-74 is superior to ¹⁸F-FDG PET/CT in the distinct subgroup of radioactive-iodine (RAI)-refractory differentiated thyroid cancer (DTC).</p><p><strong>Subjects and methods: </strong>Ten patients with recurrent DTC, detected by elevated thyroglobulin, negative RAI-scan after thyroidectomy and RAI-therapy were prospectively included. All patients underwent ¹⁸F-FAPI-74 and ¹⁸F-FDG PET/CT. The diagnostic performances were compared on a per-patient and per-lesion basis.</p><p><strong>Results: </strong>Fluorine-18-FAPI-74 PET/CT missed tumour recurrence in one patient. Fluorine-18-FDG PET/CT revealed more metastases in three patients. No management change following ¹⁸F-FAPI-74 PET/CT was documented. On a per-lesion analysis, the quantitative uptake values were significantly higher for ¹⁸F-FDG than ¹⁸F-FAPI-74 in all metastases (¹⁸F-FDG: median tumor to background ratio-TBRmax: 3.05 (1.02-9.55), ¹⁸F-FAPI-74: median TBRmax: 1.09 (0.38-5.09); P<0.001) (¹⁸F-FDG: median TBRmean: 1.71 (0.65-11.53), ¹⁸F-FAPI-74: median TBRmean: 0.64 (0.24-3.20). The detection rate was significantly higher for ¹⁸F-FDG (29/71) compared to ¹⁸F-FAPI-74 PET/CT (13/71, P<0.001).</p><p><strong>Conclusion: </strong>Fluorine-18-FDG-PET/CT outperforms ¹⁸F-FAPI-74 PET/CT in RAI-refractory DTC in this prospective analysis.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"2-7"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of bone metastases of pancreatic cancer with ¹⁷⁷Lu-DOTA-IBA.","authors":"Liyi Liu, Yueqi Zhao, Huajun Liu, Chunyin Zhang","doi":"10.1967/s002449912792","DOIUrl":"10.1967/s002449912792","url":null,"abstract":"","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"83-84"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applied research on the diagnostic value of ¹⁸F-FDG PET/CT in different subtypes mantle cell lymphoma.","authors":"Antonio Rosario Pisani, Dino Rubini, Corinna Altini, Nicola Lucarelli, Angela Gaudiano, Cristina Ferrari, Giuseppe Rubini","doi":"10.1967/s002449912785","DOIUrl":"10.1967/s002449912785","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the diagnostic value of fluorine-18-fluoro-deoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) in mantle cell lymphoma (MCL) and explore its application in distinguishing between the classic and aggressive variants of MCL.</p><p><strong>Subjects and methods: </strong>Retrospective analysis was performed on the ¹⁸F-FDG PET/CT imaging, clinical, and pathological data of 134 newly diagnosed MCL patients confirmed by pathology.</p><p><strong>Results: </strong>Among the 134 patients, 97.8% had increased ¹⁸F-FDG uptake in lymph nodes, and 88.8% had increased ¹⁸F-FDG uptake in extranodal tissues or organs. In the diagnosis of bone marrow infiltration in MCL patients, ¹⁸F-FDG PET/CT has demonstrated a high specificity rate of 86.4% and a limited sensitivity rate of 43.9%. Fluorine-18-FDG PET/CT performs well in diagnosing gastric and intestinal infiltration, with high accuracies of 85.0% and 91.7% respectively. The receiver operating characteristic (ROC) curve analysis revealed that a diagnostic threshold of maximum standardized uptake value (SUVmax) at 10.4 effectively distinguished between the classic and aggressive variants of MCL, achieving a sensitivity of 68.0%, a specificity of 80.7%, and an accuracy of 79.1%, with an area under the curve (AUC) value of 0.771.</p><p><strong>Conclusion: </strong>Fluorine-18-FDG PET/CT has a high positive detection rate in both intra-nodal and extra-nodal lesions of MCL at initial diagnosis. It exhibits high specificity and positive predictive value (PPV) in diagnosing bone marrow infiltration and possesses strong comprehensive diagnostic capabilities in gastrointestinal infiltration. Furthermore, the SUVmax can be used to distinguish between the classic and aggressive variants of MCL, and it is significantly positively correlated with the Ki-67 index, providing valuable clinical reference.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"36-43"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}